Anteris Technologies Limited
Anteris is a structural heart company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Our focus is on investing in and developing next-generation technologies with world class partners and acquiring strategic assets to grow product and service offerings. We are committed in delivering durable solutions through our Better Science & Better Design.
Anteris Technologies Ltd started its life as Allied Healthcare Group Ltd when its two parent companies Allied Medical Ltd and bioMD Ltd (ASX: BOD) merged in 2011. In 2013, the Company changed its name from Allied Healthcare Group to Admedus Ltd as part of a global branding strategy, and acquired Verigen Australia Pty Ltd (now Admedus Biomanufacturing). In 2020, Admedus Ltd changed its name to Anteris Technologies Ltd to mark the transition into becoming a Structural Heart Company with the mission to deliver the world’s most durable structural heart solutions.
The original merger of Allied Healthcare Group Ltd and bioMD Ltd created a unique healthcare company with assets in research & development, products in advanced clinical trials ready for commercialization, and a successful sales, marketing and medical device distribution business.
Anteris' clinically superior ADAPT® products have achieved 10 years without calcification or degradation and its products are currently being used in more than 135 global centres in Australia, Europe, US, Canada, Singapore, Malaysia, India, Hong Kong and the Middle East.
In late 2019, the Company sold the rights to our CardioCel® and VascuCel® patch portfolio of products, but we retained the rights to its patented ADAPT® process. This transaction allowed Anteris to concentrate on additional ADAPT® product development opportunities and provided the Company with the ability to expediate the advancement of our Heart Valve Replacement solutions and other potential products.
This enabled Anteris to focus on product development and provided us with the ability to expediate the advancement of its Heart Valve Replacement solutions and other potential products.
In 2020 Anteris started its First-in-Human trials of the DurAVR™ Heart Valve and advance the development of our DurAVR™ THV System.
Anteris is proud of its history and look forward to delivering the world’s most durable structural heart solutions through Better Science & Better Design.